The platform · LBX242
A patented engine, not a single molecule.
LBX242 is a proprietary composition engineered to overcome bacterial resistance at the molecular source — treated as a black box, protected by patent.
01
Structural disruption
LBX242 is structurally disruptive in a way that pathogens cannot route around, removing the single point of failure that resistance exploits.
02
No observed resistance
Across two decades of independent study, no evolutionary resistance has been observed — a property without parallel among conventional, single-target antibiotics.
03
Patented composition
The engine is a patented composition rather than a disclosed formula, protecting both the botanical matrix and the synthetic derivative.
De-risking matrix
Two parallel assets.
Two independently patented compositions — one botanical, one synthetic — multiply delivery options and fundamentally de-risk capital across parallel clinical pathways. Both deploy the same patented LBX242 composition.
Asset 01 · Botanical matrix
LBX242
- Classification
- Botanical matrix
- Composition
- A patented botanical matrix.
- Strategic advantage
- Three decades of broad global human use of the natural composition (beginning in 1996), qualifying the 505(b)(1) botanical pathway.
Asset 02 · Small molecule
LBX242
- Classification
- Synthetic small molecule
- Composition
- Synthetic LBX242 derivative, engineered for precision delivery.
- Strategic advantage
- Highly targeted bio-defense delivery mechanisms, qualifying the QIDP / LPAD synthetic pathway.
Route 01
The botanical express lane.
The 505(b)(1) botanical pathway, paired with three decades of broad global human use, delivers the speed and capital efficiency of a 505(b)(2) application — bypassing standard Phase 1 delays.
Estimated savings exceed ten million dollars and more than two years of clinical-trial overhead.
- 01
FDA Botanical Guidance
Codified regulatory framework for novel botanical therapeutics, distinct from the standard synthetic-drug pathway.
- 02
Three decades of human use
The composition carries three decades of broad global human use, beginning in 1996, satisfying the prior-use requirement.
- 03
Express-lane equivalence
Together, these qualify LBX242 for the speed and capital profile of a 505(b)(2) application.
- 04
Precedent: Arikayce
Arikayce (Insmed Inc.) — an antibiotic with a nanocarrier for lung delivery — successfully bypassed Phase 1 trials under the same class of FDA framework.
Route 02
The synthetic fast track.
For LBX242, two federal antimicrobial-resistance frameworks compound: QIDP under the GAIN Act grants five additional years of market exclusivity with automatic Fast Track status; the LPAD pathway scales trial burden to a limited, highly resistant patient population.
Together, these compress the approval timeline while preserving full commercial exclusivity.
QIDP · GAIN Act
+5 years exclusivity
Qualified Infectious Disease Product designation under the GAIN Act secures five additional years of market exclusivity on top of the base term, and automatically unlocks Fast Track review.
LPAD pathway
Limited Population Approval
Limited Population for Antimicrobial Drugs scales the statistical threshold to the setting: efficacy is demonstrated on a small, highly resistant cohort, compressing timeline and cost.
Convergence
Strategic asymmetry.
Biological efficacy fused with expedited FDA pathways creates a highly asymmetric upside. Three vectors compound around a single patented engine.
01
Deep biological efficacy
LBX242 acts on resistant pathogens via mechanisms that remain unopposed by known resistance pathways.
02
Regulatory fast-tracking
The GAIN Act, LPAD, and Botanical Guidance jointly bypass years of clinical delay and mitigate trial cost.
03
Capital efficiency
Multiple shots on goal via parallel routes ensure early funding achieves compounding milestones, de-risking sequential capital raises.
Catalyst
A $500K capital bridge.
A foundation catalyst of five hundred thousand dollars de-risks the subsequent one-point-five-million-dollar raise, satisfying baseline FDA toxicity requirements and establishing a safety and efficacy profile prior to Series A.
Efficacy validation
$60–80K · MicroChem Labs
In-vitro testing against the World Health Organization list of multi-drug-resistant bacteria, establishing a disease-agnostic efficacy profile.
Safety validation
$380–420K · Charles River
Formal preclinical toxicology program at Charles River Laboratories to satisfy the FDA prerequisite dossier for IND progression.
The catalyst, a $500,000 foundation, de-risks the next $1,500,000 — a $2.0 million capital raise that protects shareholder value through Series A.
Request access
Review the full clinical data deck.
Provided to qualified scientific, regulatory, and partnership parties under confidentiality.